This is an AmCham Shanghai event
13th Five Year Plan | Business Opportunities and Challenges
Presentation and Panel Discussion
China’s new 13th Five Year Plan signals a shift in Chinese government priorities away from unchecked economic development to a more human centered, environmentally sustainable development. What are the key parts of the plan and what will the impact be on foreign companies in China? AmCham Shanghai and USCBC have organized a presentation and panel discussion featuring a presentation by KPMG’s David Frey, who has had extensive meetings and discussions with the Chinese government on the plan. His presentation will be followed by a panel discussion from industry experts and leaders on the plan’s opportunities and challenges for companies in China.
ABOUT THE EVENT
Wednesday 6 April 2016 | 11.30 - 13.30
The Portman Ritz-Carlton Hotel
1376 Nanjing Xi Lu
ABOUT THE SPEAKER AND PANELISTS
David Frey is a Partner for Markets Strategy with KPMG in China. He advises multinational companies on strategic growth and expansion opportunities in China and across Asia Pacific. In addition, he leads KPMG’s US-China Strategic Corridor and has responsibility for the development of KPMG’s cross-border advisory profile among companies and governments in the world’s two largest economies. He has spent nearly twenty years in industry and consulting roles for clients in China, across Asia Pacific and in the Americas. He appears regularly as a guest commentator in print media and on CNBC and CCTV regarding China’s economic development. David’s views are called upon by both foreign governments and the China government, having served as an expert witness at a US Congressional Commission hearing in Washington on China’s Five Year Plans, chairing a roundtable session at China’s prestigious Party School and hosting numerous sessions with the Development Research Center (DRC) of the State Council regarding the financing of China’s urbanization. Additionally he has been invited to participate in several closed-door sessions with Ambassadors posted in China, and frequently provides background briefings to company Boards meeting in China.
Vijay V. Vaitheeswaran is an award-winning senior correspondent for The Economist. He joined the editorial staff in 1992 as its London-based Latin America correspondent, and later opened the magazine’s first bureau in Mexico City. From 1998 to 2006, he covered energy and the environment. From 2007 to 2011, his portfolio encompassed global health, pharmaceuticals and biotechnology. Vijay opened the newspaper’s first Shanghai bureau in 2012, and currently serves as the China Business Editor & Shanghai Bureau Chief. His latest book (published by Harper Collins) is “Need, Speed and Greed: How the New Rules of Innovation Can Transform Businesses, Propel Nations to Greatness, and Tame the World’s Most Wicked Problems.” Kirkus Reviews declared it to be the “perfect primer to the post-industrial age.” He previously co-authored “ZOOM”, with Iain Carson, and “Power to the People”, two award-winning books about the future of cars and energy. Vijay is a life member of the Council on Foreign Relations and an advisor on sustainability and innovation to the World Economic Forum. His commentaries have appeared in the Wall Street Journal, Financial Times and New York Times. He is a graduate of the Massachusetts Institute of Technology.
Eric Zwisler is currently Chairman of Cardinal Health China, a subsidiary of Cardinal Health (CAH), a Fortune 20 company. He’s been involved in healthcare businesses in Asia and particularly China for the last 26 years. Prior to his current role, he was President of Cardinal Health China for three years. Eric has also served as CEO of Zuellig Pharma Asia Pacific, a privately owned industry leading Pan Asia healthcare distribution and services company with $8.5 billion turnover and 8,000 employees located in 15 Asian countries and regions. Earlier in his career he established and built a breakthrough healthcare distribution and services business in China for Zuellig Pharma. In his role as CEO of Zuellig Pharma Asia Pacific, Eric oversaw the sale of the China subsidiary to Cardinal Health in 2010 for $470 million. Following the sale Eric returned to China to head-up the company he founded, now an integrated life sciences distribution and services company handling over $6 billion annually. Eric is a graduate of Carroll University with a degree in economics (1980) and holds an MBA (1982) and completed course work for a Masters in Chinese Studies (1987) from the University of Michigan, He holds a Chinese language certificate (1988) from the Inter-university Center for Chinese Studies (Stanford Center) in Taipei. He is fluent in Mandarin Chinese.